Scotiabank lowers Sabra Health Care REIT target to $19

0 min read     Updated on 18 Jun 2026, 09:07 PM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

Scotiabank analyst Nicholas Yulico maintained Sabra Health Care REIT with a Sector Perform rating and lowered the price target to $19 from $22.

powered bylight_fuzz_icon
43342648

*this image is generated using AI for illustrative purposes only.

Scotiabank analyst Nicholas Yulico maintained Sabra Health Care REIT with a Sector Perform rating while lowering the price target to $19 from $22. The adjustment reflects a revised outlook for the healthcare real estate investment trust.

The rating remains unchanged as Sector Perform, indicating an expectation for the stock to perform in line with the broader sector. The price target reduction suggests a more conservative valuation of the company's near-term potential.

Metric Previous New
Price Target $22 $19
Rating Sector Perform Sector Perform

What specific factors led to the revised outlook for Sabra Health Care REIT's near-term potential?

How might this price target reduction influence investor sentiment towards the healthcare REIT sector?

What are the potential risks or challenges facing Sabra Health Care REIT in the current market environment?

like15
dislike

Raymond James cuts Sabra Health Care REIT to Underperform

0 min read     Updated on 17 Jun 2026, 08:01 PM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

Raymond James analyst David Rodgers reinstated Sabra Health Care REIT's rating to Underperform from Market Perform, signaling expectations that the stock will lag behind market averages.

powered bylight_fuzz_icon
43252271

*this image is generated using AI for illustrative purposes only.

Raymond James analyst David Rodgers has reinstated the rating for Sabra Health Care REIT to Underperform from Market Perform. The adjustment signals a revised perspective on the real estate investment trust's potential stock performance relative to the broader market.

The rating change was issued by Raymond James, a financial services firm, focusing specifically on Sabra Health Care REIT, which is listed on the NASDAQ under the ticker symbol SBRA. The move from Market Perform to Underperform indicates that the analyst expects the stock to lag behind market averages.

Analyst Rating Details

The following table outlines the change in rating status:

Rating Status Previous Rating New Rating
Sabra Health Care REIT Market Perform Underperform

The reinstatement provides investors with an updated benchmark for evaluating the company's financial trajectory and market position.

What specific factors drove Raymond James to lower Sabra Health Care REIT's rating?

How might this downgrade impact Sabra Health Care REIT's stock price in the short term?

Are there broader sector challenges affecting healthcare REITs that could influence Sabra's performance?

like19
dislike